Ensure that your treatments reach their destination. Millions of people require injectable treatments, but an estimated 10% avoid treatment due to needle phobia.
3M recently completed a human tolerability study with the goal of selecting the appropriate microneedle array for use in clinical studies. This study demonstrated delivery of a 2 mL formation in 2 minutes or less on average. Additionally, the clinical study results provide foundational data in assessing the safety of the device. Clinical supplies are now available for assessment in potential development partners' trials.1
3M hollow microneedle technology is designed for efficient delivery of liquid formulations into the skin via a 1 cm2 hollow microneedle array. Microneedle delivery has been found to be less intimidating in human factors and primary market research studies.2
3M™ Hollow Microstructured Transdermal System has been created with patients in mind. This single-use delivery system designed for self-administration provides many patient-friendly features such as a textured grip for dexterity-challenged patients, a protective safety cap for the microneedle array, and an audible click for added assurance of actuation and a status indicator window with a progress bar.
By potentially reducing anxiety, microneedle delivery may improve patient compliance in some patient groups.
1 Initiation of clinical studies may require a submission for regulatory review
2 3M, data on file.
In leading up to the finalized 3M Hollow Microstructured Transdermal System design. 3M has applied a rigorous process including:
While drug PK profiles need to be evaluated on an individual basis, microneedle delivery via 3M™ Hollow Microstructured Delivery System may offer potential benefits when compared with conventional injections2:
2 3M, data on file.
From microreplication to delivery of biologics, gain a competitive edge with 3M. Take advantage of our expertise in customizing solutions to fit drug formulation needs: